Short CV:
Miriam Corredor is CEO of NoctuRNA Therapeutics, a biotech company developing a circular RNA platform for neurodegenerative and other diseases. She holds a PhD in Medicinal Chemistry from Universitat Ramon Llull, with a thesis on drug discovery for neurodegeneration, and later completed a European postdoc resulting in several high-impact publications. In addition, she earned a Master’s in Business Innovation (UPC). With over a decade of experience at CSIC and as Director of Singular Initiatives at Fundación Leitat, Miriam has built a career at the intersection of science, innovation, and entrepreneurship.
Abstract:
Circular RNAs (circRNAs) are emerging as a powerful new class of therapeutic molecules with unique advantages over traditional RNA modalities, including greater stability, efficacy, and reduced immunogenicity. NoctuRNA Therapeutics, a spin-off from Pompeu Fabra University, is developing a proprietary circRNA platform to address unmet medical needs in neurodegenerative and other currently incurable diseases. This talk will highlight the potential of circRNA-based therapies, our journey as a university spin-off, and the opportunities they open for creating novel treatments where conventional strategies have failed.
